Lore Gruenbaum, PhD, Discusses the LLS Therapy Acceleration Program

Dr. Gruenbaum, Vice President of the Therapy Acceleration Program at the Leukemia & Lymphoma Society (LLS), discusses the program’s goals and initiatives at the European Hematology Association 2024 Congress.

The foundation conducts partnerships with companies to provide funding to accelerate novel blood cancer therapies.

“We bring the perspective of the patient and our understanding of the science, based on our extensive grant program and the many [key opinion leaders] we interact with, to help companies shape their strategy for clinical development so that it benefits the patients who need therapy most,” Dr. Gruenbaum explained.